Aruna Bio has received FDA approval for its investigational new drug (IND) application, allowing AB126, its pioneering exosome therapy.

Sarepta Therapeutics Launches Participant Selection for Phase 3 Trial, EMERGENE, Investigating SRP-9003 in Limb-Girdle Muscular Dystrophy 2E/R4 Treatment.

CARsgen's candidate, CT011, has secured authorization from the NMPA to proceed with trials for GPC3-positive Ⅲa hepatocellular carcinoma patients with a significant risk of recurrence post-surgery.

Halozyme Reports Roche Granted EU Clearance for Subcutaneous Form of Tecentriq® with ENHANZE® Technology, Marking a Breakthrough in the Delivery of Immunotherapies Across Various Cancers.

Chipscreen NewWay Initiates Phase 1 Study: Administers Initial Dose of Innovative Dual-Targeting Antibody NWY001 for Advancing Cancer Immune Therapy in Individuals with Progressive Solid Cancers.

InnoCare Pharma has disclosed that the FDA has given approval to proceed with the clinical study for its BCL2 inhibitor, designated as ICP-248.

AM-Pharma B.V. has started Phase 2 trials treating patients to test its enzyme, ilofotase alfa, for preventing kidney injury post-cardiac surgery.

ExeVir Bio reports its antibodies effectively neutralize current COVID-19 Omicron strains.

Hope Medicine Inc. announces successful completion of its Phase Ib "An Open-Label Study on Safety and Efficacy of HMI-115 in Androgenetic Alopecia over 24 Weeks," advancing its research milestones.

Indapta Therapeutics Reveals Initial Treatment of Patients Using IDP-023, a Non-Self Derived NK Cell Treatment for Cancer Management.

PharmaLogic Holdings Corp. has struck a deal with clinical stage innovator ARTBIO for the production of AB001, an experimental prostate cancer treatment using lead-212.

FDA Sanctions Combination Use of Merck's KEYTRUDA (pembrolizumab) with Standard Chemoradiotherapy for Treating Stage III-IVA Cervical Cancer According to FIGO 2014 Criteria.